AI Risk Assessment Model for Complication Prevention in Plastic Surgery (Artificial Intelligence)
AI
Evidence-Based Prospective Study of the Artificial Intelligence Risk Assessment Model for Complication Prevention in Plastic Surgery
1 other identifier
observational
3,347
1 country
1
Brief Summary
The goal of this observational study is to determine if an AI-based risk assessment model can help prevent complications in plastic surgery patients by improving decision-making, providing recommendations to address risk factors, and assisting doctors in choosing the optimal timing and setting for elective plastic surgery. The study aims to answer if the AI model can effectively identify high-risk patients and what specific risk factors predict complications. Purpose: Evaluate the clinical effectiveness of an AI-based risk assessment model in preventing complications in plastic surgery patients by analyzing clinical data and patient history, providing personalized recommendations to mitigate risk factors and enhance outcomes. Hypothesis: The AI model can more accurately identify high-risk patients and provide effective recommendations to reduce complications compared to traditional methods. Participants: Individuals undergoing elective plastic surgery. They will complete an online form collecting data on age, height, weight, smoking habits, and comorbidities. The system calculates risk scores, BMI, and Caprini scores. Study Procedures: Risk assessment using the AI model, which evaluates multiple factors and generates personalized recommendations, including weight management, smoking cessation, blood pressure control, Doppler ultrasound for DVT, nutritional consultations, and specialist referrals. Recommendations are reviewed and approved by plastic surgeons. Follow-Up: The follow-up period ranges from 2 to 41 months, with a mean of 15 months. Data on patient outcomes, including complication rates and satisfaction, will be collected and analyzed. Outcomes Measured: Incidence of complications, the accuracy of the AI model in predicting complications, and its impact on improving surgical outcomes. Impact: The study aims to provide insights into AI use in plastic surgery, leading to better risk assessment tools and protocols, enhancing preoperative planning, postoperative care, and patient safety and satisfaction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2021
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2024
CompletedFirst Submitted
Initial submission to the registry
July 12, 2024
CompletedFirst Posted
Study publicly available on registry
July 18, 2024
CompletedJuly 18, 2024
July 1, 2024
3.4 years
July 12, 2024
July 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incidence of Postoperative Complications Including DVT, PTE, and ASIA Syndrome Within 2 to 41 Months Post-Surgery
Postoperative complications will be assessed using a standardized complication reporting system. Complications include but are not limited to infections, hematomas, seromas, wound dehiscence, deep vein thrombosis (DVT), and pulmonary thromboembolism (PTE). Each participant will be monitored for any complications occurring within the follow-up range of 2 to 41 months (mean = 15 months) post-surgery. The presence and severity of complications, such as severe sepsis, hemorrhage, hematoma, seroma, wound dehiscence, ASIA syndrome (diagnosed up to 6 months post-surgery), infection, and pulmonary thromboembolism, will be documented during follow-up visits. The data will be collected through clinical evaluations and patient self-reports. Specific follow-up visits will be scheduled at 1 week, 2 weeks, 1 month, 2 months, 6 months, and additional follow-ups as needed based on individual patient conditions and complications.
From enrollment to the end of treatment at 8 weeks
Study Arms (1)
Patients undergoing elective plastic surgery, evaluated with the AI-based risk assessment model.
This cohort includes patients undergoing elective plastic surgery who are evaluated using an AI-based risk assessment model. The AI model analyzes clinical data and patient history to generate personalized risk scores and recommendations to minimize surgical complications. Based on the AI-generated risk scores, patients are divided into three risk groups: low, moderate, and high-risk. The model provides tailored recommendations for each patient's altered risk factor, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to address specific risk factors and improve surgical outcomes.
Interventions
Bukret AI Risk Assessment Model is a sophisticated decision support system that evaluates clinical data and patient history to generate personalized risk scores and classify patients into risk group categories for those undergoing plastic surgery. This AI model analyzes various risk factors, including BMI, age, smoking habits, and medical history, to identify potential complications. Based on the AI-generated risk group and specific risk factors, the model provides tailored recommendations for preoperative management, such as weight management, smoking cessation, blood pressure monitoring, and specialist consultations, to minimize surgical risks and improve outcomes. This intervention aims to enhance surgical planning and patient safety by offering personalized, actionable recommendations.
Eligibility Criteria
The study population consists of patients evaluated at Bukret Plastic Surgery, a solo practice located in Buenos Aires, Argentina. This population includes individuals seeking elective plastic surgery who meet the inclusion criteria and are willing to undergo the AI-based risk assessment model evaluation. Participants are drawn from a diverse demographic background, encompassing various ages, genders, and health statuses. The focus is on those who can adhere to the preoperative and postoperative recommendations to optimize surgical outcomes and minimize complications.
You may qualify if:
- Age 18 years or older.
- Evaluated for elective plastic surgery.
- Ability to provide informed consent.
- Completion of the preoperative assessment using the AI-based risk assessment model.
- Agreement to follow preoperative and postoperative recommendations provided by Dr. Bukret, according to the AI-based risk assessment model.
You may not qualify if:
- Individuals under the age of 18.
- Patients undergoing emergency plastic surgery procedures.
- Inability to provide informed consent due to cognitive or psychological impairment.
- Pregnant or breastfeeding women.
- Patients with a history of non-compliance with medical recommendations.
- Patients currently enrolled in another clinical trial that could interfere with this study\'s outcomes.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Bukret Plastic Surgery
Buenos Aires, 1107, Argentina
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Williams E Bukret, MD, EMBA
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 12, 2024
First Posted
July 18, 2024
Study Start
January 1, 2021
Primary Completion
May 31, 2024
Study Completion
May 31, 2024
Last Updated
July 18, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- Beginning 3 months after the publication of results and continuing for 1 year.
- Access Criteria
- Researchers who wish to access the IPD and supporting information must submit a detailed research proposal outlining the planned analyses. The proposal should include the statistical methods and must be approved by an independent review committee. A data sharing agreement, which ensures the privacy and confidentiality of participants, must be signed. Requests can be submitted to the study's principal investigator via email. Proposals will be reviewed based on scientific merit, ethical considerations, and feasibility. Approval will be granted for analyses that align with the study's objectives and ethical guidelines.
All individual participant data (IPD) collected throughout the trial will be shared. This includes all disidentified data that underlie the results reported in the study publication, such as demographic data, clinical data, and outcome measures. Data will be shared in a format that ensures confidentiality and privacy of the participants. The IPD will be available to researchers who provide a methodologically sound proposal, subject to review and approval by the principal investigator. Data sharing agreements will be required to ensure the proper use of the shared data. The data will be available for 5 years following the completion of the study.